Sandra EngleSenior Principal Scientist, Pluripotent Stem Cell Biology Laboratory of the Primary Pharmacology Group Pfizer
Rudolf JaenischFounding member, Whitehead Institute and Professor of Biology MIT
Raymond KemperHead of Mechanistic Safety-US Hoffmann-La Roche Pharmaceuticals
Hans KeirsteadProfessor of Anatomy and Neurobiology University of California, Irvine
The rapid progress in our understanding of iPS cell technology has been remarkable. But the next step is using iPS cells to meet research, therapeutic and commercial objectives.
So how are you keeping up to date with the latest advances? How are other drug developers generating and using iPS cells? What about applications in research?
In our research you told us that there is no other commercial event specifically designed to help the field drive forward the practical utility of iPS cells. Until now.
For the first time, the World iPS Cell Summit delivers 19 leading industry and academic speakers who will help you tackle the key issues in translating innovative iPS cell research into drug and therapeutic development. Arm yourself with the tools you need to advance your iPS cell reprogramming, differentiation, disease modeling and drug development approaches.
What's covered on the agenda?
Who should attend?
The World iPS Cell Summit is the world’s only meeting focusing on the commercial potential of this promising science. Build relationships with industry peers and future clients by meeting and networking with all the key stakeholders involved in iPS cell research and application. This means it’s for:
1. Download a copy of the final brochure to view the agenda sessions
2. Join the discussions and network with your peers in the run up to the meeting by searching LinkedIn groups for iPS cells.
3. Something you want to share; white papers or articles? Then let us know... just email any questions to firstname.lastname@example.org
“...try to use human disease specific iPS cells differentiated into lung epithelial lineages or endothelial lineages in order to recellularize similar 3D lung scaffolds, such as from rodents or humans, to make functioning bio-artificial lungs that can be transplanted in vivo.”
“All really outstanding. A lot of industry-relevant presentations” Pfizer
“Very valuable and useful information. One of the best meetings I’ve ever attended” Millenium
“Excellent overview of pharma’s interests and opportunities” Merck
“Informative with fantastic networking opportunities, very well organized” Harvard University
“Enlightening! Was not aware of the activity in this field” Genentech
"Excellent program highlighting cutting edge work in the field. Innovative approach to meeting structure – networking and brainstorming activities were fun and useful” Novelos Therapeutics
“Outstanding meeting with first class speakers. I learned a lot and I will certainly recommend the meeting to my colleagues” Sanofi